Abstract: Embodiments of the present disclosure provide for passivated quantum dots, methods of making passivated quantum dots, methods of using passivated quantum dots, and the like.

Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: Technologies relating to generation of training data for use in training a computer-implemented ranker are described. A product name extracted from a URL in a log entry of a search log of a search engine is mapped to a catalog product name from a catalog of a website, wherein the catalog product name identifies a product that is available for acquisition by way of a webpage of a website. A query assigned to the URL in the log entry is assigned to the catalog product name due to the product name being mapped to the catalog product name. The computer-implemented ranker is trained based upon the query being assigned to the catalog product name.

Abstract: A gradient coil assembly of a magnetic resonance imaging system includes at least one gradient coil, a cooling arrangement for cooling the gradient coil, and an RF shield. The cooling arrangement includes at least one cooling tube that is configured to transport a cooling fluid and which is disposed on and in thermal contact with the gradient coil, wherein the assembly further comprises a thermal connector arrangement with at least one of a first thermal connector disposed between the RF shield and the at least one cooling tube, which provides a radially extending connection between the RF shield and the at least one cooling tube.

Abstract: A gradient coil assembly (62) for use in a Magnetic Resonance Imaging (MRI) system includes primary coils (68), shield coils (72) and a supporting structure (10) arranged between the primary coils (68) and the shield coils (72). The supporting structure (10) includes at least a supporting element (12) including a first end face (14) and at least a first recess (24) with an opening (26) in the first end face (14). The first recess (24) extends in a longitudinal direction (18) of the supporting element (12) forming a tray for receiving a passive shim bar.

Abstract: A method of jitter detection and image restoration for high-resolution TDI CCD satellite images. The method includes: obtaining a parallax image after a sub-pixel matching method relying on a correlation coefficient and least squares algorithm; transferring a jitter offset from an image space to an object space by an integral transformation function (ITF); dealing with a continuous push-broom mode of cameras in a discrete way with a denser sampling strategy according to a continue dynamic shooting model (CDSM), obtaining a specialized CDSM and feeding it back to the ITF; applying the accurate ITF to the obtained parallax image and conducting the jitter curve fitting to achieve the jitter detection; estimating a correspondent partial PSF according to the CDSM and the obtained jitter curve; carrying out an adaptive restoration based on context through optimal window Wiener filtering, by means of multiple input and single output to completes the image restoration.

Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: Embodiments of the present disclosure provide for passivated quantum dots, methods of making passivated quantum dots, methods of using passivated quantum dots, and the like.

Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

Abstract: A polar transmitter including a digital power amplifier cell that includes a first circuit and an amplifier circuit. The first circuit is configured to receive a phase modulated carrier signal and to generate a PMOS control signal and an NMOS control signal such that the PMOS control signal and the NMOS control signal have different duty cycles. The amplifier circuit is configured to receive the PMOS control signal at a PMOS transistor and the NMOS control signal at an NMOS transistor. The first circuit is configured to align the PMOS control signal and the NMOS control signal with respect to one another such that a time that the NMOS transistor and the PMOS transistor of the amplifier circuit are simultaneously conducting is minimized. The amplifier circuit is configured to generate an amplified modulated carrier signal in response to the PMOS and NMOS control signals.

Abstract: Disclosed are compounds of Formula (I?) methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.

Abstract: Embodiments of the present disclosure provide for methods of making quantum dots (QDs) (passivated or unpassivated) using a continuous flow process, systems for making QDs using a continuous flow process, and the like. In one or more embodiments, the QDs produced using embodiments of the present disclosure can be used in solar photovoltaic cells, bio-imaging, IR emitters, or LEDs.

Abstract: In an embodiment, a processor includes multiple processing engines and a power control unit. The power control unit is to: maintain a first utilization metric for a first processing engine; detect a thread transfer from a first processing engine to a second processing engine; and generate, using the first utilization metric for the first processing engine, a second utilization metric for a second processing engine. Other embodiments are described and claimed.

Abstract: The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.

Abstract: In an embodiment, a processor for performance state adjustment includes a plurality of processing engines (PEs), a power control unit, and an input/output memory management unit (IOMMU). The IOMMU is to determine a destination PE for a user interrupt based on mapping data of the IOMMU, and to send a notification of the user interrupt to the power control unit. The notification indicates the destination PE for the user interrupt. The power control unit is to adjust a performance state of the destination PE in response to the notification of the user interrupt. Other embodiments are described and claimed.

Abstract: A polar transmitter including a digital power amplifier cell that includes a first circuit and an amplifier circuit. The first circuit is configured to receive a phase modulated carrier signal and to generate a PMOS control signal and an NMOS control signal such that the PMOS control signal and the NMOS control signal have different duty cycles. The amplifier circuit is configured to receive the PMOS control signal at a PMOS transistor and the NMOS control signal at an NMOS transistor. The first circuit is configured to align the PMOS control signal and the NMOS control signal with respect to one another such that a time that the NMOS transistor and the PMOS transistor of the amplifier circuit are simultaneously conducting is minimized. The amplifier circuit is configured to generate an amplified modulated carrier signal in response to the PMOS and NMOS control signals.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt thereof. Also provided are methods of using the compounds of Formula (I) for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.